NEUROCRINE BIOSCIENCES, INC.

Classic CAH, a genetic disorder affecting adrenal glands, is treated with Crenessity, reducing steroid use and managing symptoms effectively, despite potential side effects.

The schizophrenia market is forecasted to grow to $17 billion by 2031, driven by new adjunctive therapies. The report covers 7MM, offering insights into market trends, pipeline analysis, and strategic opportunities for stakeholders.

Congenital Adrenal Hyperplasia (CAH) market, valued over USD 20M in 2023, is projected to grow at ~40% CAGR till 2034. Key players include Crinetics Pharmaceuticals, Neurocrine Biosciences, and Spruce Biosciences, developing therapies like CRN04894, Crinecerfont, and Tildacerfont. CAH, a rare endocrine disorder, lacks a cure, with treatments focusing on hormone replacement and management of symptoms.

The Congenital Adrenal Hyperplasia (CAH) market, valued at over USD 20 million in 2023, is projected to grow at a CAGR of ~40% by 2034. Key companies like Neurocrine Biosciences and Spruce Biosciences are advancing treatments, with promising therapies such as crinecerfont and tildacerfont in development. The market spans the 7MM, focusing on innovative treatments and addressing unmet needs in CAH care.

FDA approved Crenessity (crinecerfont) for classic CAH treatment, reducing glucocorticoid dependency and improving hormone control in patients aged four and older, with risks of adrenal crisis noted.

Neurocrine Biosciences announced CRENESSITY (crinecerfont), a first-in-class therapy for classic congenital adrenal hyperplasia (CAH), is now available in the U.S. Approved by the FDA, it reduces adrenal androgen production, allowing lower glucocorticoid doses. Supported by the largest CAH clinical trials, it's available through PANTHERx Rare, with Neurocrine Access Support aiding patients.

US FDA approved crinecerfont (Crenessity) for congenital adrenal hyperplasia (CAH) in adults and children aged 4+; first new therapy for CAH in 70 years. Indicated as adjunctive treatment to glucocorticoid replacement therapy, it reduces excess adrenal androgens. Based on phase 3 CAHtalyst trial data.

Novo Holdings completes $16.5B Catalent Pharma Solutions buyout. Merck pays $112M upfront for obesity pill. Ottimo Pharma raises $140M for cancer therapy. Novo Nordisk invests $1.2B in Denmark factory. Angitia Biopharmaceuticals raises $120M for musculoskeletal candidates. Novartis closes MorphoSys sites, laying off 330. SiteOne Therapeutics secures $100M for non-opioid pain drugs. Novo Nordisk's obesity drug underperforms. Bristol Myers Squibb invests $100M in BioArctic's Alzheimer antibodies. Sudan's healthcare collapses. Tonix Pharmaceuticals files NDA for fibromyalgia drug. Neurocrine Biosciences wins FDA approval for Crenessity. Edgewise Therapeutics discusses accelerated approval for Becker muscular dystrophy. FDA places partial hold on PepGen's Duchenne therapy. Checkpoint Therapeutics' immunotherapy approved. WHO opens Academy in Lyon. GSK's Jemperli earns FDA Breakthrough status. Sanofi's duvakitug shows remission in ulcerative colitis. Sandoz agrees to $275M settlement over drug pricing. Pfizer projects 2025 earnings. Mesoblast's Ryoncil approved as 1st MSC therapy for graft-vs-host disease.

Neurocrine commits to a free goods program for endocrinologists to familiarize with Crenessity's clinical profile. Open label studies will continue into 2025, with BofA Securities projecting $39.4M in 2025 sales and $1.2B peak global sales by 2034. The firm maintains a Buy rating with a $182 price objective. Neurocrine sets Crenessity's US list price at $38,333 for a 30-day supply for adults, $19,167 for pediatric patients, anticipating 90% of CAH patients will have a $12 or less monthly copay. Neurocrine Biosciences launches CRENESSITY for congenital adrenal hyperplasia in the US, with analysts expecting a gradual commercial launch. Goldman Sachs raises its price target to $182, while BMO Capital maintains a Market Perform rating at $121 and Piper Sandler confirms an Overweight rating with a $160 target.

CRENESSITY™, a first-in-class treatment for classic congenital adrenal hyperplasia (CAH), is now available in the U.S. It reduces adrenal androgen production, allowing lower glucocorticoid doses. Available exclusively through PANTHERx Rare, with Neurocrine Access Support offering assistance. FDA approval followed the largest CAH clinical trials, CAHtalyst™ Pediatric and Adult studies.